Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-Azacytidine for Muscle Contractures in Cerebral Palsy
NCT06377085Phase 1Enrolling by invitation
- Sponsor
- Shirley Ryan AbilityLab
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of azacitidine in Muscle contracture (8 arms), sponsored by Shirley Ryan AbilityLab. Primary endpoint: Dose-limiting toxicity at 2 years. Started Jul 2025; status: enrolling by invitation.
02
Drugs
azacitidine
03
Conditions
Muscle contracture
Beyond the preview
Go deeper on NCT06377085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06377085.